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ABSTRACT
We characterized the natural history of metastatic renal cell carcinoma (RCC) and identified prognostic factors
among patients who did or did not undergo allogeneic hematopoietic stem cell transplantation (HSCT). A total
of 99 patients (23 who underwent HSCT and 76 who did not) were included in the study. Overall survival rates
were comparable between the HSCT and no-HSCT groups (excluding patients with poor performance status
or brain metastasis from the latter group) at a median 17.4 months of follow-up (P  .92). In univariate
analyses, Fuhrman’s nuclear grade 4 (P  .05), high serum calcium (P  .002), or low hemoglobin levels (P 
.02), 3 or more metastatic sites (P  .02), and <12 months from diagnosis to initial recurrence (P  .04) were
identified as poor prognostic factors. In multivariate analyses, 3 or more metastatic sites (P  .005) and low
hemoglobin levels (P  .02) were poor prognostic factors. In the HSCT group, median survival times from
consultation and from transplant were 25 and 19 months for those with 0 prognostic factors (n 7) and 11 and
7 months for those with 1 or more prognostic factors (n  16). In conclusion, previous concerns that HSCT
would negatively affect long-term outcome of patients with metastatic RCC were not confirmed. Patients with
any of these poor prognostic factors should not consider HSCT for metastatic RCC. The role of allogeneic
HSCT for patients with no prognostic factors should be explored in clinical trials for patients with targeted
therapy-resistant metastatic RCC.
© 2007 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Metastatic renal cell carcinoma (RCC) carries an
xtremely poor prognosis, with 5-year survival rates of
10% [1]. Chemotherapy for metastatic RCC pro-
uces response rates of only about 15% to 30%, without
urable complete responses and little impact on survival
2]. Although cytokine therapy (eg, interleukin [IL]-2,
nterferon) is thought to be superior to conventional
ytotoxic chemotherapy for metastatic RCC, response
ates are still poor at about 15% to 20% [3-6]. (Recent advances in understanding the molecular
enetics of RCC have opened the way for the concept
f molecular-targeted therapy. Of the new agents cur-
ently being investigated (eg, antiangiogenic drugs
7-14], raf-kinase inhibitors [15-19], and the mamma-
ian target of rapamycin (mTOR) inhibitors [20-22]),
ome seem to have positive effects on survival of pa-
ients with metastatic RCC. Overall response rates to
argeted therapy have ranged from 2% to 40% [23].
Allogeneic hematopoietic stem cell transplantation
HSCT) is a well-established treatment option for he-
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K. Nakayama et al.976atologic malignancies. Allogeneic HSCT can induce
n immune-mediated graft-versus-tumor (GVT) effect
24], which has been best demonstrated against leuke-
ias and lymphomas [25,26]. In 2000, Childs et al.
27] reported a clear GVT effect with allogeneic
SCT in patients with cytokine-refractory metastatic
CC. Since that time, we and others have reported
linical evidence of GVT effects in metastatic RCC,
lthough those studies involved relatively small num-
ers of patients [28-35].
Allogeneic HSCT is associated with substantial
isks of treatment-related morbidity and mortality
TRM), primarily related to graft-versus-host disease
GVHD) and infections. Many eligible patients hesi-
ate to choose allogeneic HSCT because of its high
RM rates (reportedly 15%) [36]. In addition, a con-
iderable proportion of patients referred to transplant
linics do not meet the eligibility criteria for trans-
lant regardless of their preferences (eg, lack of an
LA-compatible donor or poor performance status
PS]). Therefore, assessing the efﬁcacy of allogeneic
SCT and its role for RCC is complex. Patients
eceiving HSCT have been highly selected and cannot
imply be compared with patients with metastatic
CC in other published studies.
In this study, we retrospectively characterized all
atients who presented to the Stem Cell Transplan-
ation Center at The University of Texas M.D.
nderson Cancer Center considering undergoing al-
ogeneic HSCT for metastatic RCC, and we identiﬁed
rognostic factors associated with prognosis among
atients who did or did not undergo allogeneic
igure 1. Derivation of sample sizes and reasons for not undergoing
ade in this study were between the HSCT group (n  23) and a su
S or brain metastases. HSCT, hematopoietic stem-cell transplantation; RSCT. This is the ﬁrst retrospective data set that
issects the natural history of metastatic RCC in pa-
ients who underwent consultation for allogeneic
SCT.
ATERIALS AND METHODS
atients
Subjects were chosen from a total of 110 patients
uspected of having metastatic RCC who were referred
etween September 1999 and November 2003 to the
tem Cell Transplantation Center at M.D. Anderson
ancer Center to consider allogeneic HSCT as a treat-
ent option. Of these 110 patients, 11 were excluded
rom the analysis (Figure 1), 4 with coexisting malig-
ancies (cervical cancer, malignant teratoma, or fol-
icular lymphoma [1 of whom had received HSCT]), 1
ith adenocarcinoma of gastrointestinal origin rather
han RCC, 4 for lack of pathologic materials for con-
rmation, and 2 for having no sign of metastatic dis-
ase at the time of the consultation. This study was
eviewed and approved by the institutional review
oard of M.D. Anderson.
The transplant group consisted of 23 patients, all of
hom met our eligibility criteria [32]. Brieﬂy, those
riteria were age 70 years or younger, with histologic
onﬁrmation of metastatic disease, excluding pure sarco-
atoid and pure transitional cell carcinoma types. Pre-
ious treatments were allowed. Response to prior ther-
py was not required. Other eligibility criteria for
ransplantation included having a related or unrelated
lantation among the no-transplant group. Most of the comparisons
the no-HSCT group (n  45) that excluded 31 patients with poortransp
bset ofCC, renal cell carcinoma.
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Hematopoietic Stem Cell Transplantation for Renal Cell Carcinoma 977LA-compatible donor, good PS (a score of 0 or 1 on
he Eastern Oncology Cooperative Group [ECOG]
cale), and adequate organ function (deﬁned as creati-
ine 2.0 mg/dL, total bilirubin 2.0 mg/dL, and left
entricular ejection fraction 50%). The preparative
egimen for the transplant consisted of ﬂudarabine (total
ose 125 mg/m2) and melphalan (140 mg/m2). GVHD
rophylaxis consisted of tacrolimus and mini-metho-
rexate (5 mg/m2 intravenously on days 1, 3, and 6).
onor lymphocyte infusion (DLI) was given if there
as no GVHD and no tumor response by 6 weeks
fter the transplant [32]. Response to therapy was
valuated at 3-month intervals. Evaluations included
hest X-ray, skeletal scintigraphy, and chest and ab-
ominal/pelvic computed tomography [32]. Disease
esponse to transplant was classiﬁed as followed: com-
lete response (CR) was the disappearance of all dis-
ase and symptoms related to the tumor for4 weeks;
artial response (PR), a50% reduction in the sum of
he products of the diameters of each measurable
esion measured on diagnostic images for 4 weeks;
inor response (MR), a reduction in measurable le-
ions too small to qualify as a PR; stable disease (SD),
o change in tumor size; and progressive disease (PD),
he appearance of new lesions or a 25% increase in
he sum of the products of diameters of any measur-
ble lesions [32].
ata Collection
For patients who did not undergo transplantation,
he reasons for not undergoing HSCT were grouped
n 1 of 5 categories: poor PS or the presence of brain
etastases; no interest; no available donor; ﬁnancial
ifﬁculties; or other. If patients had not undertaken a
earch for a donor or for ﬁnancial approval, in the
bsence of other major medical and social reasons, we
ssumed that those patients were not interested in
SCT. Follow-up was done by contacting the pa-
ients or their treating physicians.
Histologic slides were reviewed to conﬁrm the
iagnosis. Patients’ status was updated through Sep-
ember 30, 2005.
utcome Measures and Statistical Considerations
Data from all eligible patients were analyzed with
escriptive statistics. Median overall survival (OS)
ime was estimated by the method of Kaplan and
eier. A Cox proportional hazards regression model
as then used to test several factors for possible sig-
iﬁcance as predictors of OS.
ESULTS
atient Characteristics
The median follow-up time for all 99 patients was
4.8 months (range: 0.2-65.6 months). After the con- iultation, 23 patients (23%) underwent HSCT and 76
atients (77%) did not (Figure 1). Patient character-
stics are summarized in Table 1.
For the purposes of this study, further compari-
ons were made mostly between patient in the HSCT
roup and a subset of the no-HSCT group (those with
ood PS [ECOG score 2] and without brain metas-
ases). Because patients with poor PS or brain metas-
ases were considered ineligible for HSCT, including
hose patients in the analysis, it would have biased the
esults. No difference in PS was found between the
SCT group and the no-HSCT subgroup with good
S and no brain metastases (P  1.00). However, the
umber of patients who had had IL-2 therapy and the
umber of treatment cycles received before consulta-
ion were less in the no-HSCT subgroup than in the
SCT group (P .02 for both) (Table 1). Otherwise,
he characteristics were similar between groups.
In terms of types of preconsultation treatments,
he only difference found between the HSCT group
nd the entire no-HSCT group (n  76) was a history
f IL-2-based therapy; 63% of the HSCT group had
eceived IL-2-based cytokine therapies before consul-
ation, but only 37% of the no-HSCT subgroup had
eceived such therapies (P .03). Roughly 20% of the
atients in both groups had received antiangiogenic
herapies before consultation. Most of those therapies
ere thalidomide, but a few patients had received
yrosine-kinase inhibitors before consultation (4% of
he no-HSCT group and 0% of the HSCT group).
The types of treatment given after the consulta-
ion were different in the HSCT group and in the
o-HSCT group (Table 2). Forty patients in the no-
SCT group (53%) were given chemotherapy, but
nly 1 patient in the HSCT group (4%) was given
hemotherapy after consultation, which was given as
reatment after relapse (P  .001). Twenty-four pa-
ients in the no-HSCT group received thalidomide
ersus 0 in the HSCT group (P  .001). Patients in
he no-HSCT group were also more likely to have
eceived cytokine therapy (28 in no-HSCT versus 4 in
SCT [again, given as treatment after relapse]; P 
08) or tyrosine-kinase inhibitors (12 in no-HSCT
ersus 1 in HSCT, P  .09).
easons for Not Undergoing Allogeneic HSCT
The primary reasons for not undergoing alloge-
eic HSCT are shown in Figure 1. The most common
easons were poor PS or the presence of brain metas-
ases (n  31) and lack of interest on the part of the
atient (n  20). The median time between initial
isease recurrence and subsequent consultation at
.D. Anderson tended to be longer for patients with
oor PS or brain metastases than for the other sub-
roups (11.3 months versus 3.7 months for the no-
nterest group [P  .06], 3.5 months for the no-donor
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K. Nakayama et al.978roup [P  .28], and 2.6 months for the ﬁnancial-
roblem group [P  .15]).
verall Response Rate
The overall response rate (CR  PR) in the
SCT group was 26%. In terms of the best responses,
patients (17%) achieved CR, 2 (9%) achieved PR, 5
22%) achieved MR, and 5 (22%) experienced SD.
ive other patients experienced PD, and 2 patients
able 1. Patient Characteristics
Variable
HSCT
N
(N  23)
ex
Male 17
Female 6
ge: range (median)
At diagnosis 28-62 (48)
At consultation 30-63 (51)
edian time (months) from diagnosis
to consultation (range) 25.5 (2.8-151)
istology
Clear cell 15
Papillary 4
Sarcomatoid 0
Granular 2
Other 2
Unknown 0
uhrman’s nuclear grade
2 2
3 12
4 7
Unknown 2
revious IL-2 therapy
No 9
Yes 14
revious IFN therapy
No 8
Yes 15
erformance status at consultation
0 or 1 22
>2 1
revious Nephrectomy
No 0
Yes 23
o. of Abnormal Laboratory
Findings‡
0 8
1 11
2 4
3 0
NA 0
SCT indicates hematopoietic stem cell transplantation; PS/BM,
he following factors were evaluated and found to be no differen
chemotherapy regimens before cosultation, number of sites of m
Fisher’s exact test or Mantel-Haenszel chi-square test, comparin
metastases.
P value for clear cell versus nonclear cell was 0.59.
Abnormal ﬁndings were hemoglobin level 13 g/dL for males or
lactate dehydrogenase levels 1.5 times the upper limit of normied of acute GVHD (aGVHD) before evaluation for Oisease response. A total of 17 patients in the HSCT
roup (74%) eventually died, at a median 7 months
range: 0.6-28.5 months) after HSCT, a median of 11
onths (range: 3.2-37.1 months) after the initial con-
ultation (Table 3). TRM rates were 17% at day 100
nd 26% at 12 months after transplantation. The
umulative nonrelapse mortality rate was 39%.
Of the 6 patients alive at last follow-up after
SCT, 5 were alive with controlled disease (Table 4).
without
PS/BM Poor PS/BM P values*
45) (N  31) (Column 1 versus Column 2)
9 22 .32
6 9
(54) 25-68 (50)
(56) 31-69 (51)
.2-100) 17.9 (24.3-112) .09
2 20 .07†
3 8
4 0
0 1
3 0
3 2
5 3 .55
2 14
0 8
8 6
2 17 .02
3 14
6 8 .13
9 23
4 13 1
1 18
4 3 .29
1 28
6 4 .92
8 10
5 11
1 3
5 3
ance status/brain metastasis; IL-2, interleukin-2; IFN, interferon.
en the two groups: history of cytokine-based therapy, number of
tic disease.
T versus no-HSCT without poor performance status or brain
g/dL for females; corrected serum calcium level of 10 g/dL; oro-HSCT
Poor
(N 
3
25-69
25-69
9.0 (0
3
2
1
3
1
2
1
4
4
1
1
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t betwe
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g HSC
11.5ne patient was alive in CR at 28.7 months after
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ubsequent ongoing reductions in tumor mass; 3 were
live with SD at 19.1, 21.3, and 64.2 months; and 1
as alive with PD at 48.3 months (Table 4).
aGVHD developed in 15 patients, and all of those
atients were treated with corticosteroids. Of these 15
atients, 7 patients had disease response (CR or PR);
f the 9 patients who did not develop GVHD, only 1
howed disease response (P  .19).
Thirteen DLIs were performed in 8 patients. Two
f those patients (20%) developed aGVHD after DLI.
o disease responses were observed after DLI.
In the no-HSCT group, 12 patients were alive at
ast follow-up (Table 5), 5 with SD, 5 with PD, and 2
ith unknown disease status. Of the 12 survivors, at
east 5 had received targeted therapy after consulta-
ion, and 3 were alive without evidence of disease
able 2. Treatments After Consultation
Therapies
No-HSCT group
n  76
HSCT group
n  23
P valuen (%) n (%)
hemotherapy 40 (52.6) 1 (4.2) <.001
Fluorouracil 14 (18.4) 1 (4.2)
Gemcitabine 27 (35.5) 0 (0.0) <.001
Capecitabine 24 (31.6) 0 (0.0) <.001
Cisplatin,
Carboplatin 2 (2.6) 0 (0.0)
Vinblastine 2 (2.6) 0 (0.0)
Doxorubicin 3 (3.9) 0 (0.0)
Ifosfamide 2 (2.6) 0 (0.0)
Fludarabine 1 (1.3) 0 (0.0)
Methotrexate 1 (1.3) 0 (0.0)
Paclitaxel 1 (1.3) 0 (0.0)
ytokine-containing
therapy 28 (36.8) 4 (16.7) .08
IFN-based therapy 21 (27.6) 2 (8.3) .06
IL-2-based therapy 15 (19.7) 3 (12.5)
argeted therapy
(including anti-
angiogenic
therapy) 31 (40.8) 2 (8.3) .005
Thalidomide 24 (31.6) 0 (0.0) <.001
Bevacizumab 4 (5.3) 2 (8.3)
Imatinib 2 (2.6) 0 (0.0)
Sorafenib 4 (5.3) 0 (0.0)
Erlotinib 3 (3.9) 1 (4.2)
SU-5416 5 (6.6) 0 (0.0)
CP-675,206 1 (1.3) 0 (0.0)
ABT510 1 (1.3) 0 (0.0)
Any tyrosine-
kinase inhibitor 12 (15.8) 1 (4.2) .09
ocal therapy
Palliative surgery 2 (2.6) 2 (8.3)
Radiation therapy 10 (13.2) 2 (8.3)
Unknown 8 (10.5) 0 (0.0)
SCT indicates hematopoietic stem cell transplantation; IFN, in-
terferon; IL-2, interleukin-2.rogression.
Aurvival
OS rates from the time of the consultation for the
SCT group and the no-HSCT subgroup (excluding
he 31 patients with poor PS or brain metastases from
he no-HSCT group) are shown in Figure 2. The
edian survival times were 15.2 months (range: 3.2-
5.6 months) for the HSCT group and 18 months
range: 1.9-62.6 months) for the no-HSCT subgroup
excluding patients with poor PS or brain metastases)
P  .92). The median survival times from diagnosis
ere 42.8 months (range: 16-200 months) for the
SCT group and 30.4 months (range: 5.9-126
onths) for the no-HSCT subgroup (P  .44). The
edian survival time from transplantation for the
SCT group was 8.4 months (range: 0.6-64.2
onths). Seventeen patients in the HSCT group and
3 patients in the no-HSCT subgroup died during the
tudy period. In the HSCT group, the median time
rom diagnosis to death was 35.6 months (range: 16.0-
4.3 months). In no-HSCT subgroup, median time
rom diagnosis to death was 24.1 months (range: 5.9-
24.5 months) (P  .97).
rognostic Factors
We used both univariate and multivariate analyses
o analyze possible prognostic factors. Excluded from
he analyses were patients with poor PS or brain me-
astasis (n  31), who were originally considered to
ave poor prognosis, and 5 other patients in the no-
SCT group because of unavailable laboratory data at
he time of consultation. Findings from the analyses of
actors possibly associated with OS time (from con-
ultation) for the 63 remaining subjects are summa-
ized in Table 6. In univariate analyses, Fuhrman’s
uclear grade 4 (P  .05), high serum calcium level
corrected level 10 g/dL) (P  .002), low hemoglo-
in level (13 g/dL for males or 11.5 g/dL for
emales) (P  .02), 3 or more number of sites of
etastatic disease (P  .02), and 12 months from
iagnosis to initial recurrence before consultation
P  .04) were identiﬁed as poor prognostic factors
able 3. Causes of Death after HSCT
Causes
Number of
Patients (%)
Days from
HSCT Until
Death
rogressive disease
8 (47)
Median 245
(range:
65-885)
raft-versus-host disease 2 (12) 19 and 48
neumonia 3 (17) 77, 175, and 743
cute respiratory distress
syndrome 1 (6) 85
hrombotic thrombocyto
penic purpura 2 (12) 175 and 590
cute myocardial infarction 1 (6) 76
Table 4. Characteristics of Survivors in the Transplant Group
Patient
No.
Cell
Source
Metastatic Sites at
Consultation
Treatment before
Consultation
Disease
Status at
Transplant
Sites of Grade
II-IV Acute
GVHD
No.
of
DLIs
Sites of
Chronic
GVHD
Overall
Best
Response
Treatment After
Transplant
Disease Status
at Last
Follow-Up*
1 MSD PB Remaining kidney,
pancreas
Nephrectomy, IL-2,
IFN
PD Skin 0 Skin, mouth SD — SD, 19.1 mo
2 MSD PB Lung,
retroperitoneal
mass
Nephrectomy PD Skin, GI 0 — CR — SD, 64.2 mo
3 MSD PB Lung Nephrectomy,
IFN,IL-2,
fluorouracil
PD GI 0 Skin, mouth CR — CR, 28.7 mo
4 MSD PB Bone, lung Nephrectomy,
fluorouracil, IL-2,
IFN; fluorouracil,
gemcitabine;
thalidomide, RT
SD — 1 — MR TAE PD, 48.3 mo
5 MSD PB Retroperitoneal,
liver
Nephrectomy, IFN,
FUDR;
thalidomide, IL2;
capecitabine,
gemcitabine
PD Skin 0 Skin SD anti-VEGF
elrotinib
SD, 21.3 mo
6 MSD PB Lung, liver,
pancreas
Nephrectomy, RT;
capecitabine,
gemcitabine
PD — 0 — MR — MR, 6.0 mo
GVHD indicates graft-versus-host disease; DLI, donor lymphocyte infusion; MSD, matched sibling donor; PB, peripheral blood; IL-2, interleukin-2; IFN, interferon; PD, progressive disease; SD, stable
disease; GI, gastrointestinal; CR: complete remission, TAE, transcatheter arterial embolization; RT, radiation therapy; FUDR, ﬂoxuridine; VEGF, vascular endothelial growth factor; MR, minor
response.
*Shown as time since transplant.
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Hematopoietic Stem Cell Transplantation for Renal Cell Carcinoma 981mong all patients. Multivariate analyses identiﬁed 3
r more metastatic sites (P  .005) and low hemoglo-
in level (P  .02) as being poor prognostic factors
Table 6). Survival curves for patients in the HSCT
roup (n  23) and the no-HSCT subgroup (n  40,
xcluding patients with poor PS or brain metastasis or
navailable lab data) according to number of risk fac-
ors (number of metastatic sites  3 and low hemo-
lobin level) are shown in Figure 3. In the HSCT
roup, median survival time from the time of consul-
ation for patients with 0 risk factors (n  7) was 25
onths; that for patients with 1 or more prognostic
actors (n  16) was 11 months (P  .01) (Figure 3A).
n the no-HSCT subgroup (excluding patients with
oor PS or brain metastasis or unavailable lab data),
he median survival time from the consultation was 22
onths for those with 0 prognostic factors (n  21)
nd 9 months for those with 1 or more prognostic
actors (n  19) (P  .03) (Figure 3B).
ISCUSSION
We retrospectively identiﬁed prognostic factors
ssociated with poor survival, not only for those who
ad HSCT but also for those who had not. In this
tudy, we did not see a difference in OS between the
SCT and the no-HSCT group. Thus, previous con-
erns that HSCT would negatively affect long-term
utcome of patients with metastatic RCC were not
onﬁrmed. This lack of difference in OS may have
esulted from the somewhat high TRM rates, which
re comparable to or slightly higher than those re-
orted in previous studies [27-30,33-35]. These mor-
ality rates may have offset any survival beneﬁt pro-
igure 2. OS of patients who did undergo HSCT and those who
id not (no-HSCT), excluding patients with poor PS or brain
etastasis (BM), calculated from the time of the consultation. Me-
ian survival times: HSCT group, 15 months (range: 3.2-65.6
onths); no-HSCT subgroup, 18 months (range: 19.0-62.6
onths).duced by HSCT in this patient population. InTa Pa
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K. Nakayama et al.982ddition, a longer interval between diagnosis and con-
ultation and having had more previous treatments
relative to the no-HSCT group) may also have offset
ny survival beneﬁt.
Our results indicate that patients with at least 1 of
he prognostic factors identiﬁed in this study should
ot undergo HSCT. Our prognostic factors could be
igure 3. A, OS from consultation of patients who did undergo
SCT according to number of prognostic factors. Median survival
imes: 0 prognostic factors, 24.5 months (range: 17.4-65.6 months);
or more prognostic factors, 10.7 months (range: 3.2-46.0 months)
P  .01). PF, number of prognostic factors. B, OS from consulta-
ion of a subset of 40 patients who did not undergo HSCT (no-
SCT) (excluding 31 patients with poor PS or brain metastases and
patients for whom laboratory data were not available at consul-
ation) according to number of prognostic factors. Median survival
imes: 0 prognostic factors, 22 months (range: 5.0-62.6 months); 1
r more prognostic factors, 9 months (range: 1.9-59.6 months) (P
able 6. Prognostic Factors Associated with Overall Survival from the
Variables
O
Uni
uhrman’s nuclear grade 4 .
igh serum calcium .
ow hemoglobin .
ime between diagnosis and recurrence <12 months .
etastatic organ sites >3 .
I indicates conﬁdence interval; HR, hazard ratio.p03). PF, number of prognostic factors.seful tools for identifying patients who are likely to
ave better versus worse prognosis after HSCT. Be-
ause our analyses were based on the time of ﬁrst
onsultation for HSCT, our analysis is unlike other
tudies in which prognostic factors were sought for
atients with similar disease status (eg, after nephrec-
omy, after cytokine therapy, or with cytokine-refrac-
ory disease) [37-40]. Our ﬁndings may be helpful for
redicting prognosis in outpatient settings, where
hysicians ordinarily see and provide consultations for
uch patients whether they undergo HSCT or not.
When this study was reported, 3 other studies had
een published regarding prognostic factors affecting
S for patients who received HSCT [41-43]. Two of
hose studies indicated that high PS, high lactate de-
ydrogenase (LDH) levels, and high C-reactive pro-
ein levels [41], or high PS and low hemoglobin levels
42], were associated with poor prognosis. The other
tudy indicated that the existence of chronic GVHD
cGVHD), a history of DLI, 3 metastatic sites, and
Karnofsky score 70% were associated with good
rognosis [43]. In our study, neither high PS nor high
DH level was associated with poor prognosis (we did
ot examine C-reactive protein), because we excluded
atients with a PS scores of 2 or more. In fact, when
atients with high PS were included in the analyses,
oth high PS (2) and high LDH level were signiﬁ-
antly associated with poor prognosis in univariate
nalysis (P  0.01 and 0.05) (data not shown). Aside
rom C-reactive protein levels, cGVHD, and DLI, all
f these factors had already been reported as prognos-
ic factors for no-HSCT patients with metastatic RCC
37,38,44-49], suggesting that these factors may affect
he survival of patients who undergo HSCT as well as
hose who do not. In other words, the prognosis for
atients undergoing HSCT depends on the original
isease prognosis, and hence, HSCT should be con-
idered before disease-related PS becomes poor. In
ur study, about 30% of patients were already ineli-
ible for HSCT at the time of consultation because of
aving high PS scores or brain metastases. This means
hat delays in seeking consultation may have rendered
ome of these patients ineligible for a transplant. Early
eferral to a transplant service is recommended for
Consultation
Survival P Values
Hazard Ratio 95% CI for HRMultivariate
.02 2.29 1.16-4.52
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neligible.
On the other hand, our ﬁndings also showed that
atient refusal was another major reason for not un-
ergoing a transplant. In our sample, signiﬁcantly
ewer patients in the no-HSCT group had been given
L-2 therapy, and patients in the no-HSCT group had
ad fewer numbers of treatment cycles than was true
n the HSCT group. Logically, one might assume that
atients who had not yet been given cytokine therapy
r several cycles of chemotherapy may have elected to
eceive 1 or both of those rather than a transplant,
ossibly because the cytokine therapy and chemother-
py were perceived as being safer. This indicates that
arly referral to a transplant service does not neces-
arily encourage patients to choose HSCT. Clearly,
lose cooperation between oncologists, stem cell
ransplantation physicians, and patients will be needed
o avoid missing the best time for HSCT.
Recent results of a Cancer and Leukemia Group B
CALGB)—Intergroup phase II study of allogeneic
SCT for metastatic RCC [50] showed that no ob-
ective responses were observed in the 22 patients
nrolled despite the presence of both aGVHD and
GVHD. On the other hand, a recent European study
howed that the overall response rate (CR  PR) in a
iven allogeneic HSCT for metastatic RCC was 29%
43], a ﬁnding similar to ours. One possible reason for
his discrepancy is that more of the patients in the
ALGB study may have had poor prognostic factors;
or example, 45% of the patients in that study had 3 or
ore metastatic sites, whereas only 18% of the pa-
ients in our study did. The report of the European
tudy did not include information on number of met-
static disease sites.
Recent studies of the efﬁcacy of targeted therapy
or metastatic RCC have shown response rates of 2%
o 40% [23]. In our study, relatively few of the patients
eceived targeted therapy, probably because few clin-
cal trials of targeted therapy had been undertaken
uring our study period. In our HSCT group, 16
70%) of the 23 patients got a transplant during or
efore 2002, and the other 7 patients got a transplant
fter 2002. Of the 8 patients who eventually died after
ransplant of disease progression, 5 died in 2001 or
002, and only 3 died during or after 2003 (data not
hown); it is possible that patients who underwent
ransplantation early during the study period would
ave been ineligible to participate in clinical trials of
yrosine-kinase inhibitors. The use of targeted therapy
ould be expected to increase as its efﬁcacy becomes
etter established. Given the importance of low TRM
ates during targeted therapy, allogeneic HSCT could
erhaps best be applied, on a trial basis, to patients
ith disease refractory to targeted therapy. Further-
ore, the effectiveness of targeted therapy for pro-
ressive disease after HSCT remains unclear. Thispeculation should be validated in the context of clin-
cal trials.
Our results must be interpreted cautiously; the
etrospective nature of our study may have introduced
arious selection biases, which can render the results
isleading. Nonetheless, it is clear that HSCT is an
ctive treatment for some patients with no poor prog-
ostic factors. In this study, of the 6 survivors of
SCT, 1 achieved CR, and this patient was in still CR
hen this paper was written; another 4 patients are
nder observation without additional treatment.
hese facts may indicate that these patients beneﬁtted
rom HSCT. Over the past 5 years, TRM rates asso-
iated with HSCT have dropped to 10% through
mprovements in transplant technology and experi-
nce. However, future efforts are needed to establish
eans of separating GVT effects from GVHD. Ideal
reatment approaches, especially for targeted-therapy-
esistant RCC, need to be established. The potential
fﬁcacy of HSCT for metastatic RCC that does not
espond to targeted therapies (eg, sorafenib, sutinib)
hould be tested in clinical trials to conclusively de-
ermine whether transplantation is a treatment option
or this deadly disease.
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